Dr. Donald Eagerton, M.D.

Medicare patients and services

Medicare patients, 2024

1,841

Services billed

281,980

Patients’ average age

74

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 27 companies reported 182 payments worth $45,945 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in South Carolina →

Industry-funded research

Named as a principal investigator on 14 industry-funded studies in 2025, from 6 companies. The companies reported $1,216,518 in research payments for these studies, mostly to the institutions running them.

• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
  ModernaTX, Inc. · Completed · NCT06602024
• A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
  ModernaTX, Inc. · Completed · NCT06864143
• A phase 2, parallel-group, double-blind study to investigate the safety and tolerability of LY3549492 compared with placebo in adult participants 55 to 80 years of age and bmi within 22 to 25 kg/M2
  Eli Lilly and Company
• A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
  Eli Lilly and Company · Completed · NCT05929079
• A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
  Eli Lilly and Company · Completed · NCT05882045
• A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes
  Boehringer Ingelheim Pharmaceuticals, Inc.
• A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM
  Amgen Inc.
• A phase 3 randomized observerblinded study to evaluate the safety tolerability and immunogenicity of a combined modified rna vaccine candidate against COVID19 and influenza in healthy individuals
  Pfizer Inc.
• A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
  ModernaTX, Inc. · Completed · NCT05330975
• Phase III efficacy for obesity - with T2DM
  Boehringer Ingelheim Pharmaceuticals, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Endocrinology & Diabetes clinicians in Myrtle Beach

• Ashley E. Clarke, MD
• Gauri Dhir, M.D.
• Alimitha M. Kodali, MD
• Chelsea Lane, MD
• Anne G. Larochelle, M.D.
• Jocelyn A. Myers, M.D.
• Sahana Parthasarathy, M.D